1
|
de Marneffe N, Dulgheru R, Ancion A, Moonen M, Lancellotti P. Cardiac amyloidosis: a review of the literature. Acta Cardiol 2022; 77:683-692. [PMID: 35852493 DOI: 10.1080/00015385.2021.1992990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Cardiac amyloidosis is a rare disease associated with severe morbidity and mortality. There are three main types of amyloidosis associated with cardiac involvement: light chain (AL), familial or senile (ATTR) and secondary amyloidosis (AA). Cardiac amyloidosis often results in heart failure with preserved left ventricular ejection fraction, may display echocardiographic features of restrictive cardiomyopathy associated with left ventricular hypertrophy or mimic hypertrophic obstructive cardiomyopathy. However, left ventricular systolic dysfunction and normal wall thickness can sometimes be encountered. Imaging studies (echocardiography, bone scintigraphy, cardiac magnetic resonance) and blood and urine analysis are usually the main tools for the diagnosis. Sometimes, a tissue biopsy may be necessary. Treatment, which is constantly improving, will be carried out on two fronts: treatment of the symptoms and complications that the disease already caused and prevention of additional amyloid deposits while managing the concomitant complications. The purpose of this article is to review the management of cardiac amyloidosis.
Collapse
Affiliation(s)
- Nils de Marneffe
- Department of Cardiology, University Hospital of Liege, Liege, Belgium
| | - R Dulgheru
- Head of Clinic, Department of Cardiology, University Hospital of Liege, Liege, Belgium
| | - A Ancion
- Head of Clinic, Department of Cardiology, University Hospital of Liege, Liege, Belgium
| | - M Moonen
- Head of Clinic, Department of Cardiology, University Hospital of Liege, Liege, Belgium
| | - P Lancellotti
- Professor at the University of Liege, Head of the Cardiology Department, Director of the Cardiovascular GIGA, University Hospital of Liege
| |
Collapse
|
2
|
van der Boon RMA, den Dekker WK, Meuwese CL, Lorusso R, von der Thüsen JH, Constantinescu AC, Manintveld OC, Delnoij TSR, van der Heijden JJ, van Mieghem NMDA, den Uil CA. Safety of Endomyocardial Biopsy in New-Onset Acute Heart Failure Requiring Veno-Arterial Extracorporeal Membrane Oxygenation. Circ Heart Fail 2021; 14:e008387. [PMID: 34344163 DOI: 10.1161/circheartfailure.121.008387] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Endomyocardial biopsy (EMB) has an important role in determining the pathogenesis of new-onset acute heart failure (new-AHF) when noninvasive testing is impossible. However, data on safety and histopathologic outcomes in patients requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is lacking. METHODS A retrospective, multicenter cohort of patients undergoing EMB while requiring VA-ECMO for new-AHF between 1990 and 2020 was compared with a cohort of nontransplant related biopsies not requiring VA-ECMO. Primary end point of the study was to determine the safety of EMB. Additionally, we describe the underlying pathogenesis causing new-AHF based on histopathologic examination of the samples obtained. RESULTS A total of 23 patients underwent EMB while requiring VA-ECMO (10.0%), 125 (54.3%) during an unplanned admission, and 82 (35.7%) in elective setting. Major complications occurred in 8.3% of all procedures with a significantly higher rate in patients requiring VA-ECMO (26.1% versus 8.0% versus 3.7%, P=0.003) predominately due to the occurrence of sustained ventricular tachycardia or need of resuscitation (13.0% versus 3.2% versus 1.2%, P=0.02). EMB led to a histopathologic diagnosis in 78.3% of the patients requiring VA-ECMO which consisted primarily of patients with myocarditis (73.9%). CONCLUSIONS EMB in patients requiring VA-ECMO can be performed albeit with a substantial risk of major complications. The risk of the procedure was offset by a histopathologic diagnosis in 78.3% of the patients, which for the majority consisted of patients with myocarditis. The important therapeutic and prognostic implications of establishing an underlying pathogenesis causing new-AHF in this population warrant further refinement to improve procedural safety.
Collapse
Affiliation(s)
- Robert M A van der Boon
- Department of Cardiology (R.M.A.v.d.B., W.K.d.D., A.C.C., O.C.M., N.M.D.A.v.M., C.d.U.), Erasmus Medical Center Rotterdam, the Netherlands
| | - Wijnand K den Dekker
- Department of Cardiology (R.M.A.v.d.B., W.K.d.D., A.C.C., O.C.M., N.M.D.A.v.M., C.d.U.), Erasmus Medical Center Rotterdam, the Netherlands
| | - Christiaan L Meuwese
- Department of Intensive Care (C.d.U., C.L.M.), Erasmus Medical Center Rotterdam, the Netherlands.,Department of Cardiology and Intensive Care, Utrecht Medical Center, the Netherlands (C.L.M., J.J.v.d.H.)
| | - Roberto Lorusso
- Department of Cardiology and Intensive Care, Maastricht University Medical Center, the Netherlands (R.L., T.S.R.D.)
| | - Jan H von der Thüsen
- Department of Pathology (J.H.v.d.T.), Erasmus Medical Center Rotterdam, the Netherlands
| | - Alina C Constantinescu
- Department of Cardiology (R.M.A.v.d.B., W.K.d.D., A.C.C., O.C.M., N.M.D.A.v.M., C.d.U.), Erasmus Medical Center Rotterdam, the Netherlands
| | - Olivier C Manintveld
- Department of Cardiology (R.M.A.v.d.B., W.K.d.D., A.C.C., O.C.M., N.M.D.A.v.M., C.d.U.), Erasmus Medical Center Rotterdam, the Netherlands
| | - Thijs S R Delnoij
- Department of Cardiology and Intensive Care, Maastricht University Medical Center, the Netherlands (R.L., T.S.R.D.)
| | - Joris J van der Heijden
- Department of Cardiology and Intensive Care, Utrecht Medical Center, the Netherlands (C.L.M., J.J.v.d.H.)
| | - Nicolas M D A van Mieghem
- Department of Cardiology (R.M.A.v.d.B., W.K.d.D., A.C.C., O.C.M., N.M.D.A.v.M., C.d.U.), Erasmus Medical Center Rotterdam, the Netherlands
| | - Corstiaan A den Uil
- Department of Cardiology (R.M.A.v.d.B., W.K.d.D., A.C.C., O.C.M., N.M.D.A.v.M., C.d.U.), Erasmus Medical Center Rotterdam, the Netherlands.,Department of Intensive Care (C.d.U., C.L.M.), Erasmus Medical Center Rotterdam, the Netherlands.,Department of Intensive Care, Maasstad Hospital, Rotterdam, the Netherlands (C.d.U.)
| |
Collapse
|
3
|
Poullot E, Oghina S, Kalsoum S, Damy T. [Cardiac amyloidosis]. Ann Pathol 2021; 41:25-37. [PMID: 33422349 DOI: 10.1016/j.annpat.2020.11.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Revised: 11/27/2020] [Accepted: 11/29/2020] [Indexed: 01/15/2023]
Abstract
Different types of amyloid deposits involve the heart. Transthyretin and light chain amyloidosis are the most frequent. Diagnostic performance, typing and treatments have improved in the last decade, and prognosis of cardiac amyloidosis is now significantly better thanks to targeted therapies. In this article, we will describe the clinical manifestations of cardiac amyloidosis, the diagnostic approach and detail the characteristics and specific treatments of the most frequent types of cardiac amyloidosis. We will focus on the histopathological aspects, especially on the importance of amyloid typing.
Collapse
Affiliation(s)
- Elsa Poullot
- Département de pathologie, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre français de référence de l'amylose cardiaque (CRAC), réseau Cardiogen, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, Créteil, France.
| | - Silvia Oghina
- Centre français de référence de l'amylose cardiaque (CRAC), réseau Cardiogen, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, Créteil, France; Département de Cardiologie, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, Créteil, France
| | - Sarah Kalsoum
- Département de pathologie, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre français de référence de l'amylose cardiaque (CRAC), réseau Cardiogen, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, Créteil, France
| | - Thibaud Damy
- Centre français de référence de l'amylose cardiaque (CRAC), réseau Cardiogen, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, Créteil, France; Département de Cardiologie, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, Créteil, France
| |
Collapse
|